Supercharging Immunotherapy

go down
Our Science & Technologies

Our Difference

Hookipa Pharma Inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind, we created unique and cutting-edge technologies which reprogram and stimulate the immune system.

Our Arenavirus technologies, Vaxwave®, a replication-deficient viral vector, and TheraT®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and CD8+ T cells. Both, Vaxwave® and TheraT®, can be administered repeatedly while maintaining their efficacy. TheraT® induced CD8+ T cell responses to tumor antigens to reach frequencies and potencies matching or exceeding those observed after adoptive T cell therapy. Hookipa’s “off-the-shelf” viral vectors are administered systemically. They target dendritic cells in vivo and activate the immune system. In immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic).

At Hookipa we have successfully completed a Phase 1 trial of a Vaxwave®-based prophylactic vaccine to protect against cytomegalovirus (CMV) infections. A proof-of-concept trial in solid organ transplant patients will start imminently. We have forged a landmark partnership with Gilead Sciences Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. We are building a proprietary immune-oncology pipeline by targeting TheraT® towards HPV+ head and neck squamous cell carcinoma and prostate cancer.

Our Work


Hookipa is committed to responsibly developing critical programs where TheraT® and Vaxwave® can make the biggest difference for the most people. Our science and technologies have demonstrated the possibility of highly potent antibody and T cell responses while maintaining safety, even with repeated administrations.

Compound Phase
HB-101 Vaxwave® 1
HB-201 TheraT® PRECLIN
HB-202 TheraT® DISC
HB-301 TheraT® DISC
Next Generation Antigen DISC

Scientific advisory board

How to work with us


Hookipa is dedicated to utilizing the full potential of its two product platforms Vaxwave® and TheraT®. Vaxwave® is focused on the development of prophylactic vaccines to prevent infectious diseases and TheraT® enables Hookipa to develop immuno-oncology therapies and therapeutic vaccines.

We are open for strategic partnerships based on both platforms which reflect the potential of the technology, provide performance related downstream revenues while preserving growth opportunities for Hookipa in the future.

We look forward to hearing from you!

Presenting our team


Hookipa is a dedicated team united by the desire to find solutions for people with untreatable cancers and infectious diseases. Our leadership brings together significant achievements in immunology and building successful biotech companies to demand the kind of innovation necessary to make things happen.

Who we work with